Clinical Trials

17 enrolled

Leukemia, Myeloid, Acute

NCT03132454 2026-04-15

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05038592 2026-04-14

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Phase 1/2 Active not recruiting

64 enrolled

Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT01627041 2026-04-13

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

178 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT01861314 2026-04-13

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

15 enrolled

Leukemia, Myeloid, Acute

NCT03041688 2026-04-13

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

58 enrolled

Leukemia, Myeloid, Acute

NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

22 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT03844815 2026-03-04

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

26 enrolled

Leukemia, Myeloid, Acute

NCT03974217 2026-02-25

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

13 enrolled

Leukemia

NCT03164057 2026-01-28

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

206 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

16 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04874480 2026-01-09

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

9 enrolled

Leukemia

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

Phase 1/2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04657081 2025-12-08

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

101 enrolled

Leukemia, Myeloid, Acute

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

6 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04188405 2025-11-20

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

20 enrolled

Phase 3 Active not recruiting

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT04229979 2025-10-01

REGAL

127 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02890329 2025-09-09

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

54 enrolled 15 charts

Phase 1/2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04086264 2025-08-14

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

218 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT04891757 2025-07-10

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

144 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04476199 2025-01-06

Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT

100 enrolled

Leukemia, Myeloid, Acute

NCT04623944 2024-12-27

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

61 enrolled

Phase 3 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05177731 2024-10-03

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

188 enrolled